Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Burden of disease in patients with chronic hepatitis C in the Austrian REAL study.

Gschwantler M, Bamberger T, Graziadei I, Maieron A, Katalinic N, Stauber R.

Wien Klin Wochenschr. 2019 Jan;131(1-2):8-16. doi: 10.1007/s00508-018-1404-2. Epub 2018 Nov 14.

PMID:
30430232
2.

Increased KCNJ18 promoter activity as a mechanism in atypical normokalemic periodic paralysis.

Soufi M, Ruppert V, Rinné S, Mueller T, Kurt B, Pilz G, Maieron A, Dodel R, Decher N, Schaefer JR.

Neurol Genet. 2018 Oct 3;4(5):e274. doi: 10.1212/NXG.0000000000000274. eCollection 2018 Oct.

3.

Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding-A national multicentre study.

Pfisterer N, Riedl F, Pachofszky T, Gschwantler M, König K, Schuster B, Mandorfer M, Gessl I, Illiasch C, Fuchs EM, Unger L, Dolak W, Maieron A, Kramer L, Madl C, Trauner M, Reiberger T.

Liver Int. 2019 Feb;39(2):290-298. doi: 10.1111/liv.13971. Epub 2018 Oct 17.

PMID:
30248224
4.

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.

Flamm S, Reddy KR, Zadeikis N, Hassanein T, Bacon BR, Maieron A, Zeuzem S, Bourliere M, Calleja JL, Kosloski MP, Oberoi RK, Lin CW, Yu Y, Lovell S, Semizarov D, Mensa FJ.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):527-535.e6. doi: 10.1016/j.cgh.2018.07.003. Epub 2018 Sep 10.

5.

Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.

Beinhardt S, Al-Zoairy R, Kozbial K, Stättermayer AF, Maieron A, Stauber R, Strasser M, Zoller H, Graziadei I, Rasoul-Rockenschaub S, Trauner M, Ferenci P, Hofer H.

Liver Int. 2018 Jul;38(7):1188-1197. doi: 10.1111/liv.13652. Epub 2018 Jan 31.

PMID:
29197145
6.

Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.

Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, Graziadei I, Trauner M, Steindl-Munda P, Hofer H, Ferenci P.

Liver Int. 2018 Jun;38(6):1028-1035. doi: 10.1111/liv.13629. Epub 2017 Dec 1.

PMID:
29136329
7.

Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P.

Wien Klin Wochenschr. 2017 Nov;129(Suppl 3):135-158. doi: 10.1007/s00508-017-1262-3. Epub 2017 Oct 23.

8.

Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.

Gschwantler M, Laferl H, Vogel W, Korak W, Moser S, Hofer H, Bauer B, Schleicher M, Bognar B, Bischof M, Stauber R, Maieron A, Ferenci P; Austrian Hepatitis Study Group.

Wien Klin Wochenschr. 2018 Jan;130(1-2):54-61. doi: 10.1007/s00508-017-1263-2. Epub 2017 Sep 12.

PMID:
28900714
9.

Letter: retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals.

Kozbial K, Aberle SW, Susser S, Al-Zoairy R, Moser S, Stättermayer AF, Maieron A, Gschwantler M, Stauber R, Graziadei I, Zoller H, Beinhardt S, Holzmann H, Munda-Steindl P, Hofer H, Sarrazin C, Ferenci P.

Aliment Pharmacol Ther. 2017 Jan;45(2):373-375. doi: 10.1111/apt.13887. Epub 2016 Dec 1. No abstract available.

10.

von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.

Rutter K, Etschmaier A, Ferlitsch M, Maieron A, Hametner S, Horvatits T, Paternostro R, Salzl P, Reiberger T, Peck-Radosavljevic M, Quehenberger P, Hofer H, Trauner M, Ferenci P, Ferlitsch A.

Dig Liver Dis. 2016 Oct;48(10):1194-9. doi: 10.1016/j.dld.2016.06.033. Epub 2016 Jul 19.

PMID:
27476467
11.

Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment.

Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-Radosalvjevic M, Trauner M, Hofer H, Ferenci P.

J Hepatol. 2016 Oct;65(4):856-858. doi: 10.1016/j.jhep.2016.06.009. Epub 2016 Jun 16. No abstract available.

PMID:
27318327
12.

DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.

Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, Stättermayer AF, Stauber R, Strasser M, Zoller H, Watschinger B, Schmidt A, Trauner M, Hofer H, Maieron A.

Transpl Int. 2016 Sep;29(9):999-1007. doi: 10.1111/tri.12799. Epub 2016 Jul 7.

13.

Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.

Stern R, Hametner S, Ramona AZ, Moser S, Karpi A, Laferl H, Stauber RE, Zoller HM, Maieron A, Vogel W, Graziadei I, Gschwantler M, Kozbial K, Freissmuth C, Hofer H, Ferenci P.

Am J Gastroenterol. 2016 May;111(5):744-5. doi: 10.1038/ajg.2016.39. No abstract available.

PMID:
27151123
14.

The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.

Hametner S, Ferlitsch A, Ferlitsch M, Etschmaier A, Schöfl R, Ziachehabi A, Maieron A.

PLoS One. 2016 Feb 19;11(2):e0149230. doi: 10.1371/journal.pone.0149230. eCollection 2016.

15.

Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutations.

Stättermayer AF, Traussnigg S, Dienes HP, Aigner E, Stauber R, Lackner K, Hofer H, Stift J, Wrba F, Stadlmayr A, Datz C, Strasser M, Maieron A, Trauner M, Ferenci P.

J Hepatol. 2015 Jul;63(1):156-63. doi: 10.1016/j.jhep.2015.01.034. Epub 2015 Feb 9.

PMID:
25678388
16.

Drug fever due to a single dose of pantoprazole.

Schiller D, Maieron A, Schöfl R, Donnerer J.

Pharmacology. 2014;94(1-2):78-9. doi: 10.1159/000364781. Epub 2014 Sep 13.

PMID:
25228460
17.

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L Jr, Hu YB, Podsadecki T, Bernstein B.

Gastroenterology. 2014 Aug;147(2):359-365.e1. doi: 10.1053/j.gastro.2014.04.045. Epub 2014 May 9.

18.

SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.

Dieterich D, Asselah T, Guyader D, Berg T, Schuchmann M, Mauss S, Ratziu V, Ferenci P, Larrey D, Maieron A, Stern JO, Ozan M, Datsenko Y, Böcher WO, Steinmann G.

Antimicrob Agents Chemother. 2014 Jun;58(6):3429-36. doi: 10.1128/AAC.02497-13. Epub 2014 Apr 7.

19.

Commentary: what factors are important in diagnosing hepatic fibrosis? Authors' reply.

Maieron A, Ferlitsch M.

Aliment Pharmacol Ther. 2014 Mar;39(5):546. doi: 10.1111/apt.12612. No abstract available.

20.

Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C.

Maieron A, Salzl P, Peck-Radosavljevic M, Trauner M, Hametner S, Schöfl R, Ferenci P, Ferlitsch M.

Aliment Pharmacol Ther. 2014 Feb;39(3):331-8. doi: 10.1111/apt.12564. Epub 2013 Dec 5.

21.

Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.

Stättermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, Beinhardt S, Datz C, Scherzer TM, Steindl-Munda P, Gschwantler M, Trauner M, Hofer H, Ferenci P.

Aliment Pharmacol Ther. 2014 Jan;39(1):104-11. doi: 10.1111/apt.12547. Epub 2013 Nov 10.

22.

Long-term outcomes of patients with Wilson disease in a large Austrian cohort.

Beinhardt S, Leiss W, Stättermayer AF, Graziadei I, Zoller H, Stauber R, Maieron A, Datz C, Steindl-Munda P, Hofer H, Vogel W, Trauner M, Ferenci P.

Clin Gastroenterol Hepatol. 2014 Apr;12(4):683-9. doi: 10.1016/j.cgh.2013.09.025. Epub 2013 Sep 25.

PMID:
24076416
23.

A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection.

Beinhardt S, Payer BA, Datz C, Strasser M, Maieron A, Dorn L, Grilnberger-Franz E, Dulic-Lakovic E, Stauber R, Laferl H, Aberle JH, Holzmann H, Krall C, Vogel W, Ferenci P, Hofer H.

J Hepatol. 2013 Nov;59(5):972-7. doi: 10.1016/j.jhep.2013.06.028. Epub 2013 Jul 10.

PMID:
23850880
24.

Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.

Scherzer TM, Stättermayer AF, Stauber R, Maieron A, Strasser M, Laferl H, Schwarzer R, Datz C, Rutter K, Beinhardt S, Steindl-Munda P, Hofer H, Ferenci P.

J Hepatol. 2013 Nov;59(5):964-71. doi: 10.1016/j.jhep.2013.06.030. Epub 2013 Jul 10.

PMID:
23850877
25.

Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral.

Rutter K, Hofer H, Beinhardt S, Dulic M, Gschwantler M, Maieron A, Laferl H, Stättermayer AF, Scherzer TM, Strassl R, Holzmann H, Steindl-Munda P, Ferenci P.

Aliment Pharmacol Ther. 2013 Jul;38(2):118-23. doi: 10.1111/apt.12350. Epub 2013 May 26.

26.

Tuberculous sepsis during antiviral HCV triple therapy.

Hametner S, Monticelli F, Kern JM, Schöfl R, Ziachehabi A, Maieron A.

J Hepatol. 2013 Sep;59(3):637-8. doi: 10.1016/j.jhep.2013.05.005. Epub 2013 May 10. No abstract available.

27.

Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II).

Peck-Radosavljevic M, Angermayr B, Datz C, Ferlitsch A, Ferlitsch M, Fuhrmann V, Häfner M, Kramer L, Maieron A, Payer B, Reiberger T, Stauber R, Steininger R, Trauner M, Thurnher S, Ulbrich G, Vogel W, Zoller H, Graziadei I; Austrian Society of Gastroenterology and Hepatology.

Wien Klin Wochenschr. 2013 Apr;125(7-8):200-19. doi: 10.1007/s00508-013-0337-z. Epub 2013 Apr 12.

PMID:
23579878
28.

Efficacy and safety of oral chelators in treatment of patients with Wilson disease.

Weiss KH, Thurik F, Gotthardt DN, Schäfer M, Teufel U, Wiegand F, Merle U, Ferenci-Foerster D, Maieron A, Stauber R, Zoller H, Schmidt HH, Reuner U, Hefter H, Trocello JM, Houwen RH, Ferenci P, Stremmel W; EUROWILSON Consortium.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1028-35.e1-2. doi: 10.1016/j.cgh.2013.03.012. Epub 2013 Mar 28.

PMID:
23542331
29.

Teicoplanin therapy leading to a significant decrease in viral load in a patient with chronic hepatitis C.

Maieron A, Kerschner H.

J Antimicrob Chemother. 2012 Oct;67(10):2537-8. doi: 10.1093/jac/dks217. Epub 2012 Jun 11. No abstract available.

PMID:
22687891
30.

Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.

Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C, Peck-Radosavljevic M, Sieghart W.

Radiology. 2012 May;263(2):590-9. doi: 10.1148/radiol.12111550. Epub 2012 Mar 21.

PMID:
22438359
31.

Capsule retention in a Zenker's diverticulum.

Ziachehabi A, Maieron A, Hoheisel U, Bachl A, Hagenauer R, Schöfl R.

Endoscopy. 2011;43 Suppl 2 UCTN:E387. doi: 10.1055/s-0030-1256931. Epub 2012 Jan 24. No abstract available.

PMID:
22275012
32.

Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.

Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, Staettermayer AF, Datz C, Scherzer TM, Strassl R, Bischof M, Stauber R, Bodlaj G, Laferl H, Holzmann H, Steindl-Munda P, Ferenci P, Hofer H.

Gastroenterology. 2012 Jan;142(1):78-85.e2. doi: 10.1053/j.gastro.2011.09.039. Epub 2011 Sep 24.

PMID:
22192885
33.

Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.

Scherzer TM, Stättermayer AF, Strasser M, Laferl H, Maieron A, Stauber R, Datz C, Dulic-Lakovic E, Steindl-Munda P, Hofer H, Ferenci P.

Hepatology. 2011 Nov;54(5):1518-26. doi: 10.1002/hep.24546.

PMID:
22006276
34.

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.

Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M.

Aliment Pharmacol Ther. 2011 Oct;34(8):949-59. doi: 10.1111/j.1365-2036.2011.04823.x. Epub 2011 Aug 24.

35.

Bleeding Dieulafoy lesions of the small bowel: a systematic study on the epidemiology and efficacy of enteroscopic treatment.

Dulic-Lakovic E, Dulic M, Hubner D, Fuchssteiner H, Pachofszky T, Stadler B, Maieron A, Schwaighofer H, Püspök A, Haas T, Gahbauer G, Datz C, Ordubadi P, Holzäpfel A, Gschwantler M; Austrian Dieulafoy-bleeding Study Group.

Gastrointest Endosc. 2011 Sep;74(3):573-80. doi: 10.1016/j.gie.2011.05.027. Epub 2011 Jul 29.

PMID:
21802676
36.

Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial.

Maieron A, Metz-Gercek S, Scherzer TM, Laferl H, Fischer G, Bischof M, Gschwantler M, Ferenci P.

BMC Res Notes. 2011 Jun 29;4:220. doi: 10.1186/1756-0500-4-220.

37.

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Datz C, Maieron A, Dulic-Lakovic E, Kessler HH, Steindl-Munda P, Strasser M, Krall C, Ferenci P.

Clin Gastroenterol Hepatol. 2011 Apr;9(4):344-350.e2. doi: 10.1016/j.cgh.2010.07.019. Epub 2010 Aug 20.

PMID:
20728570
38.

Antiviral treatment of chronic hepatitis C in clinical routine.

Maieron A, Metz-Gercek S, Hackl F, Ziachehabi A, Fuchsteiner H, Luger C, Mittermayer H, Schöfl R.

Wien Klin Wochenschr. 2010 Apr;122(7-8):237-42. doi: 10.1007/s00508-010-1364-7.

PMID:
20503023
39.

[4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009].

Peck-Radosavljevic M, Deutsch J, Ferenci P, Graziadei I, Hofer H, Holzmann H, Huber WD, Laferl H, Maieron A, Stauber R, Vogel W.

Wien Klin Wochenschr. 2010 May;122(9-10):280-302. doi: 10.1007/s00508-009-1298-0. Epub 2010 May 4. German.

PMID:
20443069
40.

Chronic hepatitis C in Austria, 1992-2006: genotype distribution and demographic factors.

Maieron A, Metz-Gercek S, Hackl F, Luger C, Ziachehabi A, Strauss R, Schöfl R, Mittermayer H.

Euro Surveill. 2010 Feb 25;15(8):19492.

41.

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.

Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group.

Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. doi: 10.1053/j.gastro.2009.10.058. Epub 2009 Nov 10.

PMID:
19909752
42.

Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria.

Metz-Gercek S, Maieron A, Strauss R, Wieninger P, Apfalter P, Mittermayer H.

BMC Infect Dis. 2009 May 13;9:61. doi: 10.1186/1471-2334-9-61.

43.

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.

Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M.

Oncologist. 2009 Jan;14(1):70-6. doi: 10.1634/theoncologist.2008-0191. Epub 2009 Jan 14.

44.

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group.

Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27.

PMID:
18503773
45.

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K; Austrian Hepatitis Study Group.

Hepatology. 2008 Jun;47(6):1816-23. doi: 10.1002/hep.22262.

PMID:
18454510
46.

Polycystic kidney disease and infertility: case report and literature review.

Manno M, Marchesan E, Tomei F, Cicutto D, Maruzzi D, Maieron A, Turco A.

Arch Ital Urol Androl. 2005 Mar;77(1):25-8. Review.

PMID:
15906786
47.

Multicenter retrospective evaluation of capsule endoscopy in clinical routine.

Maieron A, Hubner D, Blaha B, Deutsch C, Schickmair T, Ziachehabi A, Kerstan E, Knoflach P, Schoefl R.

Endoscopy. 2004 Oct;36(10):864-8.

PMID:
15452781
48.

[Conservative management of ectopic pregnancy].

Lui A, D'Ottavio G, Rustico MA, Conoscenti G, Fischer Tamaro F, Meir YJ, Maieron A, Mandruzzato GP.

Minerva Ginecol. 1997 Mar;49(3):67-72. Italian.

PMID:
9173340
49.

[The indications for the management of fetuses with choroid plexus cysts].

Maieron A, Rustico M, Pecile V, Natale R, D'Ottavio G, Fischer Tamaro L, Conoscenti G, Meir YJ, Mandruzzato GP.

Minerva Ginecol. 1996 Apr;48(4):125-33. Italian.

PMID:
8767554
50.

Fetal heart screening in low-risk pregnancies.

Rustico MA, Benettoni A, D'Ottavio G, Maieron A, Fischer-Tamaro I, Conoscenti G, Meir Y, Montesano M, Cattaneo A, Mandruzzato G.

Ultrasound Obstet Gynecol. 1995 Nov;6(5):313-9.

Supplemental Content

Loading ...
Support Center